Amgen (AMGN) Says EC Approves BLINCYTO For Use In Pediatric Patients With Philadelphia Chromosome-Negative R/R B-Cell Precursor ALL
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
